Despite recent advances in diagnostic and therapeutic advances in antifungal research, aspergillosis still remains a leading cause of morbidity and mortality. One
Aspergillosis remains a significant threat to public health, and, in spite of continuous efforts to improve timely diagnosis and clinical therapies, mortality caused by this disease remains unacceptably high [1, 2] . Current therapeutic options for treating Aspergillus-induced disorders include antifungal agents such as polyenes, azoles and echinocandins [3, 4] . Thus the discovery of new antifungal compounds remains important given the need to address the development of drug resistance in pathogenic fungi [5] [6] [7] . One approach to accomplishing this goal is to prepare new derivatives of existing drugs with broad spectrum activity and enhanced pharmacokinetic properties. As part of our on-going efforts to use lipases [8] [9] [10] [11] [12] , which catalyze reactions with high degree of chemo-, regio-and stereoselectivity in organic synthesis, we became interested in preparing new antifungals using biocatalysis.
Fluconazole, introduced in 1990, is a bis-triazole antifungal drug which possesses interesting pharmacokinetic properties, such as low plasma binding affinity, good water solubility, low first pass metabolism, high oral bioavailability and a long half-life, all of which should make it a drug of choice for treating fungal infections [13, 14] . On the other hand, fluconazole has been reported to exhibit only limited activity against Aspergillus infections [15] , which has led to many reports concerning the synthesis of various types of fluconazole derivatives and their chiral separation/resolution into constituent enantiomers [16] [17] [18] [19] . We now report the use of Candida antarctica lipase (CAL-B) in catalysing the addition of amines to an achiral epoxide to yield optically enriched fluconazole analogues in which one of the triazole rings is replaced by n-alkylamino and cycloalkylamino substituents. To the best of our knowledge, the work reported herein is the first direct synthesis of optically enriched fluconazole analogues using biocatalytic methods. In vitro assays show that the optically enriched analogues exhibit more potent antifungal activity than the corresponding racemic mixtures. Interestingly, this bioactivity can be enhanced by their encapsulation in dextran-based nanoparticles [20] .
Results

Synthesis of fluconazole analogues. A series of linear and cyclic alkylamines
was screened for reaction with the epoxide ring of (±)-1-[2-(2, 4-difluorophenyl)oxiranylmethyl]-1H-[1,2,4]-triazole (1, Figure 1 ) in a number of different organic solvents. Three different immobilized lipases were also evaluated for their ability to catalyze this reaction: Candida rugosa lipase (CRL), porcine pancreatic lipase (PPL) and CAL-B. Although the ring-opening reactions catalysed by CRL and PPL were of no practical utility, when the reaction was performed in the presence of CAL-B in tetrahydrofuran (THF) as solvent, the desired products (3a-j, 5a and 5b) were obtained with good yields in optically enriched forms ( Figure 1 , and Tables S1 and S2 in Supporting Information). Very importantly, all of the twelve novel fluconazole analogues formed in the lipase-catalyzed reactions were optically active showing that aminolysis of the racemic starting epoxide (±)-1 had proceeded in an enantioselective fashion (Table S1 ). These twelve compounds could also be prepared in racemic form, as viscous oils in 75-80 % yields, by direct reaction of the alkylamines with the racemic epoxide precursor (±)-1 in THF at 55 o C. The time taken for complete consumption of aliphatic amines 2a-j, 4a and 4b in the CAL-B catalyzed reaction varied between 18h and 28h, which was considerably shorter than the 48-56 h required for the chemical addition of the amines (Table S2 in and mass spectra), and by comparison to literature data for known compounds 3b, 3c, 5a and 5b [21, 22] .
Although the enantiomeric enrichment of the fluconazole analogues prepared by lipase-catalyzed addition was not established, we were able to assign the absolute configuration of the major enantiomer using the optical activity of the unreacted epoxide isolated from the reaction mixture. These samples rotated polarized light in a positive (+) direction, meaning that the recovered, unreacted epoxide was enriched in the enantiomer for which the stereogenic centre has the (S) configuration (Table S1 in Supporting Information) [23] . CAL-B therefore preferentially employs (-)-R-1 in the aminolysis reaction and, assuming a standard S N 2 mechanism for reaction of the amine with the epoxide, we can deduce that the fluconazole analogues must be enriched in the (-)-S-enantiomer ( Figure 1 ). These experiments used standard microbroth dilution (MDA), disc diffusion (DDA) and spore germination inhibition (PSGI) assays [24, 25] . We note that the MDA assay is based on the same basic principle as that used in the CLSI micro-dilution protocol. The only difference between the two assays is that CLSI uses RPMI medium to prepare diluted drug solutions rather than the Sabouraud dextrose broth (a medium used to culture Aspergillii in the laboratory) used by us to determine the MIC of the fluconazole derivatives. As recommended in CLSI protocols, we carefully on June 20, 2017 by CARDIFF UNIVERSITY http://aac.asm.org/ Downloaded from monitored MDA parameters with respect to preparation of the test compounds, medium preparation, temperature, inoculum size, incubation time, minimum inhibitory concentration (MIC)/endpoint determination, data recording and interpretation of results to ensure the validity and quality of our results. On this point, we note that a previous study from our laboratory [26] showed that results with RPMI 1640 or RPMI 1640 containing glucose were not different from those obtained by using Sabouraud dextrose broth.
Antifungal activities of the fluconazole analogs Pathogenic
On the basis of their MIC values, all the compounds exhibited moderate to good anti-Aspergillus activities, with the analogue (-)-S-3d being more potent than the commercially available fluconazole ( Table 1 ). We also observed that optically
and (-)-S-5b were more active than the corresponding racemates. These data also confirm that introducing a linear aliphatic alkyl side chain is important for imparting antifungal activity, as reported previously [23, 24] . On the other hand, when additional, "distal" Nsubstituted alkyl groups were present, as in compounds (-)-S-3g a n d (-)-S-3h, antifungal activity was completely lost (Table 1) . Compounds 3j and 5a exhibited no biological activity in microbroth dilution assays and were not studied further. Our work also shows that the length of the alkyl side chain is an important factor in determining activity, i.e. the compound (-)-S-3d, containing an n-hexyl moiety, has higher activity than (-)-S-3a, (-)-S-3b and (-)-S-3c, which contain ethyl, n-propyl and n-butyl groups, respectively (Table 1) . Decreasing the linker chain length also led to higher activity. Optically enriched (-)-S-3d was the most potent compound against Aspergillus fumigatus (Table 1) [20] , and can be used for controlled release of pharmacologically active substances [27] . We therefore 
Anti-Aspergillus activity and cytotoxicity of (-)-S-3d encapsulated in O-
alkylated dextran nanoparticles. We next examined the effect of nanoparticle encapsulation on the activity of (-)-S-3d against Aspergillus fumigatus using a microbroth dilution assay (Figure 3 
Conclusions
Reacting alkylamines with a racemic epoxide precursor (Figure 1) in the presence of immobilized lipase CAL-B in THF provides a simple approach for the preparation of optically enriched fluconazole analogs, which appear to exhibit better antifungal activity against Aspergillus than fluconazole. Although the extent to which the enzyme catalyzes the coupling reaction in an enantioselective manner remains to be determined, we have been able to assign the (S)-configuration to the stereogenic centre of the enantiomer that exhibits biological activity, assuming that (i) the aminolysis reaction proceeds with its usual chemical mechanism, and (ii) only one enantiomer has antifungal activity. Given the difficulty of single-step chemical strategies for the preparation of chiral fluconazoles in optically enriched form, we anticipate that the enzymatic methodology reported herein will have significant impact in this approach to obtaining novel variants of existing antifungal drugs.
The most active analogue prepared in this study, (-)-S-3d, is more potent against Aspergillus fumigatus than fluconazole, having MIC values of 8-16 µg/mL in a series of in vitro assays. Perhaps more importantly for drug discovery, the anti-Aspergillus potency of this compound is enhanced (MIC 1.6-4.0 µg/mL) by encapsulation in derivatized nanoparticles, with minimal in vitro cytotoxic effects at concentrations of up to 2 mg/mL against human erythrocytes and cell lines of human origin. 2-(2',4'-Difluorophenyl)-1-hexylamino-3-(1''',2''',4''')triazol-1'''-yl- (Table   1 ). recorded. MICs in this assay (Table 1) correspond to fluconazole analog concentrations resulting in inhibition of spore germination.
Materials and Methods
General procedure for the CAL-B catalysed synthesis of optically
(-)-S-
Disc diffusion assay
In vitro cytotoxicity assays. Two approaches were performed to assess the cytotoxicity of the fluconazole analogues. First, using a standard haemolytic assay [28] , erythrocytes from healthy individuals were suspended in phosphate buffered saline (PBS) to give a 2 % suspension (v/v). These cells were then incubated with various concentrations of each compound for 1 h at 37 °C before being pelleted by centrifugation at 3000 x g for 10 min. The percentage haemolysis was then calculated from the optical density at 450 nm of the supernatant (Figure 4a ). The effect of solvent and PBS on erythrocyte viability was also checked. Triton X-100 (Sigma Chemicals, USA) was used for complete haemolysis of the erythrocytes.
In an alternate approach, an MTT-based assay [29] 
